171 related articles for article (PubMed ID: 35868194)
1. Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches.
Vathiotis IA; Johnson JM; Luginbuhl A; Cognetti D; Curry J; Argiris A
Cancer Treat Rev; 2022 Sep; 109():102437. PubMed ID: 35868194
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant PD-1/PD-L1 axis blockade for patients with head and neck squamous cell carcinoma.
Huang S; Xiong C; Tan K
Am J Otolaryngol; 2023; 44(6):103985. PubMed ID: 37442083
[TBL] [Abstract][Full Text] [Related]
3. Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy.
Vathiotis IA; Johnson JM; Argiris A
Cancer Treat Rev; 2021 Jun; 97():102192. PubMed ID: 33819755
[TBL] [Abstract][Full Text] [Related]
4. The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer.
Qiao XW; Jiang J; Pang X; Huang MC; Tang YJ; Liang XH; Tang YL
Front Immunol; 2020; 11():1721. PubMed ID: 33072064
[TBL] [Abstract][Full Text] [Related]
5. [The research progress of PD-1/L1 inhibitors application in the treatment of head and neck squamous cell carcinoma].
Song P; Yan X; Jiang Y; Ye Y; Wang J; Han P
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2022 Apr; 36(4):315-320. PubMed ID: 35511629
[No Abstract] [Full Text] [Related]
6. Neoadjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma: Expecting Its Application in Temporal Bone Squamous Cell Carcinoma.
Shi MW; Huang J; Sun Y
Curr Med Sci; 2023 Apr; 43(2):213-222. PubMed ID: 36971976
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck.
Saada-Bouzid E; Peyrade F; Guigay J
Curr Opin Oncol; 2019 May; 31(3):146-151. PubMed ID: 30893146
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
Leidner R; Crittenden M; Young K; Xiao H; Wu Y; Couey MA; Patel AA; Cheng AC; Watters AL; Bifulco C; Morris G; Rushforth L; Nemeth S; Urba WJ; Gough M; Bell RB
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963014
[TBL] [Abstract][Full Text] [Related]
9. A systematic review of neoadjuvant and definitive immunotherapy in locally advanced head and neck squamous cell carcinoma.
Nindra U; Hurwitz J; Forstner D; Chin V; Gallagher R; Liu J
Cancer Med; 2023 May; 12(10):11234-11247. PubMed ID: 36934434
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant immunotherapy prior to surgery for mucosal head and neck squamous cell carcinoma: Systematic review.
Amin N; Maroun CA; El Asmar M; Alkhatib HH; Guller M; Herberg ME; Zhu G; Seiwert TY; Pardoll D; Eisele DW; Fakhry C; Gourin CG; Mandal R
Head Neck; 2022 Feb; 44(2):562-571. PubMed ID: 34825751
[TBL] [Abstract][Full Text] [Related]
11. Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma.
Hanna GJ; Adkins DR; Zolkind P; Uppaluri R
Oral Oncol; 2017 Oct; 73():65-69. PubMed ID: 28939078
[TBL] [Abstract][Full Text] [Related]
12. Revisiting the concept of neoadjuvant and induction therapy in head and neck cancer with the advent of immunotherapy.
Smussi D; Mattavelli D; Paderno A; Gurizzan C; Lorini L; Romani C; Bignotti E; Grammatica A; Ravanelli M; Bossi P
Cancer Treat Rev; 2023 Dec; 121():102644. PubMed ID: 37862833
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant immunotherapy in head and neck cancer: Rationale, current evidence and future perspective.
Cabezas-Camarero S; Pérez-Segura P
Crit Rev Oncol Hematol; 2022 Jan; 169():103569. PubMed ID: 34890800
[TBL] [Abstract][Full Text] [Related]
14. Current landscape of immunotherapy trials in locally advanced and high-risk head and neck cancer.
Park R; Park JC
Immunotherapy; 2021 Aug; 13(11):931-940. PubMed ID: 34100301
[TBL] [Abstract][Full Text] [Related]
15. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
Front Immunol; 2021; 12():645170. PubMed ID: 33897693
[TBL] [Abstract][Full Text] [Related]
16. Introducing Checkpoint Inhibitors Into the Curative Setting of Head and Neck Cancers: Lessons Learned, Future Considerations.
Nenclares P; Rullan A; Tam K; Dunn LA; St John M; Harrington KJ
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-16. PubMed ID: 35522916
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for head and neck squamous cell carcinoma: current status and perspectives.
Daste A; Larroquette M; Gibson N; Lasserre M; Domblides C
Immunotherapy; 2024 Feb; 16(3):187-197. PubMed ID: 38126161
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.
Poulose JV; Kainickal CT
World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989
[TBL] [Abstract][Full Text] [Related]
19. [The Immune Checkpoints Inhibitors for Head and Neck Cancer].
Yokota T
Gan To Kagaku Ryoho; 2019 Jan; 46(1):21-27. PubMed ID: 30765636
[TBL] [Abstract][Full Text] [Related]
20. Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma.
Zech HB; Moeckelmann N; Boettcher A; Muenscher A; Binder M; Vettorazzi E; Bokemeyer C; Schafhausen P; Betz CS; Busch CJ
Future Oncol; 2020 Dec; 16(36):3035-3043. PubMed ID: 32902312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
